Cargando…

Flavin containing monooxygenase 2 regulates renal tubular cell fibrosis and paracrine secretion via SMURF2 in AKI-CKD transformation

In the follow-up of hospitalized patients with acute kidney injury (AKI), it has been observed that 15-30% of these patients progress to develop chronic kidney disease (CKD). Impaired adaptive repair of the kidneys following AKI is a fundamental pathophysiological mechanism underlying renal fibrosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Longfei, Zha, Hongchu, Huang, Jing, Shi, Lang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558214/
https://www.ncbi.nlm.nih.gov/pubmed/37800598
http://dx.doi.org/10.3892/ijmm.2023.5313
Descripción
Sumario:In the follow-up of hospitalized patients with acute kidney injury (AKI), it has been observed that 15-30% of these patients progress to develop chronic kidney disease (CKD). Impaired adaptive repair of the kidneys following AKI is a fundamental pathophysiological mechanism underlying renal fibrosis and the progression to CKD. Deficient repair of proximal tubular epithelial cells is a key factor in the progression from AKI to CKD. However, the molecular mechanisms involved in the regulation of fibrotic factor paracrine secretion by injured tubular cells remain incompletely understood. Transcriptome analysis and an ischemia-reperfusion injury (IRI) model were used to identify the contribution of flavin-containing monooxygenase 2 (FMO2) in AKI-CKD. Lentivirus-mediated overexpression of FMO2 was performed in mice. Functional experiments were conducted using TGF-β-induced tubular cell fibrogenesis and paracrine pro-fibrotic factor secretion. Expression of FMO2 attenuated kidney injury induced by renal IRI, renal fibrosis, and immune cell infiltration into the kidneys. Overexpression of FMO2 not only effectively blocked TGF secretion in tubular cell fibrogenesis but also inhibited aberrant paracrine activation of pro-fibrotic factors present in fibroblasts. FMO2 negatively regulated TGF-β-mediated SMAD2/3 activation by promoting the expression of SMAD ubiquitination regulatory factor 2 (SMURF2) and its nuclear translocation. During the transition from AKI to CKD, FMO2 modulated tubular cell fibrogenesis and paracrine secretion through SMURF2, thereby affecting the outcome of the disease.